Haleon (HLN) Payables (2021 - 2026)

Haleon's (HLN) quarterly Payables came in at -$7.7 billion in Q2 2026, down 26.28% on a QoQ basis from -$6.1 billion in Q4 2025.

Haleon (HLN) Payables (2021 - 2026) Analysis & Trends

Haleon (HLN) has 6 years of Payables data on file, last reported at -$7.7 billion in Q2 2026.

Quarterly Payables changed N/A year-over-year to -$7.7 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$7.7 billion (changed N/A YoY) and the FY2025 annual result came in at -$6.1 billion, down 314.22% from the prior year.
Payables retreated to -$7.7 billion in Q2 2026, from -$6.1 billion in the prior quarter.
In the past five years, Payables ranged from a high of $4.7 billion in Q4 2024 to a low of -$7.7 billion in Q2 2026.
A 5-year average of -$2.0 billion and a median of -$4.9 billion in 2022 frame the typical range for Payables.
Annual changes were most pronounced in 2024 — Payables advanced 8.95% — and 2025, when it tumbled 230.16%.
Tracing HLN's Payables over 5 years: stood at $4.2 billion in 2022, then increased by 3.67% to $4.3 billion in 2023, then increased by 8.95% to $4.7 billion in 2024, then plunged by 230.16% to -$6.1 billion in 2025, then declined by 26.28% to -$7.7 billion in 2026.
The last three Payables figures came in at -$7.7 billion (Q2 2026), -$6.1 billion (Q4 2025), and $4.7 billion (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Payables (Qtr)
1	Haleon	43.65 Bn	42.68 Bn	-	-7.73 Bn
2	Teva Pharmaceutical Industries	43.09 Bn	39.44 Bn	2.15 Bn	2.72 Bn
3	Zoetis	31.54 Bn	29.86 Bn	1.05 Bn	673.00 Mn
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	2.80 Bn
5	United Therapeutics	22.11 Bn	19.45 Bn	683.80 Mn	497.80 Mn
6	Viatris	18.77 Bn	17.88 Bn	1.46 Bn	1.73 Bn
7	Neurocrine Biosciences	15.62 Bn	15.23 Bn	935.80 Mn	808.30 Mn
8	Elanco Animal Health	12.07 Bn	11.54 Bn	798.00 Mn	427.00 Mn
9	Dr Reddys Laboratories	10.09 Bn	9.93 Bn	-	986.00 Mn
10	Alkermes	8.20 Bn	7.54 Bn	397.90 Mn	332.47 Mn

Download Data